As the incidence of malignant melanoma increases, researchers are seeking ways to accurately and reproducibly measure tumor volume and therapy response. Computer-aided volumetry may be an answer.
As the incidence of malignant melanoma increases, researchers are seeking ways to accurately and reproducibly measure tumor volume and therapy response. Computer-aided volumetry may be an answer.
Dr. Michael Fabel-Schulte of the department of radiology at the German Cancer Research Center in Heidelberg and colleagues tested 3D semiautomated segmentation and volumetry of lymph nodes in 25 patients with malignant metastatic melanoma. CT scanning covered the neck, chest, abdomen, and pelvis.
Fabel-Schulte presented the results at the 2006 European Congress of Radiology.
Two independent readers evaluated 120 suspicious lymph nodes by using volume, time, segmentation quality, and number of corrections. Additionally, 20 lymph nodes were segmented manually.
Segmentation quality was rated acceptable to excellent in 81% by reader one and 79% by reader two. Correlation of the volume was highly significant between both readers.
Readers manually corrected 15% of the lymph nodes. The average time for automated segmentation per lymph nodes was 70 to 100 seconds, compared with 180 to 200 seconds per lymph nodes for the primary manual segmentation. Encouraged by the results, researchers suggest further study in a larger patient population.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.